- Home
- MBBC vs MREO Comparison
MBBC vs MREO Comparison
Compare MBBC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBBC | MREO |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United Kingdom |
| Employees | 35 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 50.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MBBC | MREO |
|---|---|---|
| Price | $15.10 | $0.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 1.0K | ★ 889.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.02 | $0.20 |
| 52 Week High | $15.79 | $2.37 |
Technical Indicators
Market Signals| Indicator | MBBC | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 48.20 |
| Support Level | $14.63 | $0.28 |
| Resistance Level | $15.48 | $0.35 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 75.86 | 39.54 |
Price Performance
Historical ComparisonAbout MBBC Marathon Bancorp Inc.
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).